This time we are looking on the crossword clue for: Tiny particle.
it’s A 13 letters crossword puzzle definition. See the possibilities below.
Did you find what you needed?
We hope you did!. If you are still unsure with some definitions, don’t hesitate to search them here with our crossword solver.
Possible Answers: ATOM, IOTA, ION, MOTE, PROTON, FLECK, ATOMY.
Last seen on: –Irish Times Simplex – Feb 22 2020
–Irish Times Simplex – Dec 18 2019
–Premier Sunday – King Feature Syndicate Crossword – Jul 7 2019
–Irish Times Simplex Crossword – Aug 10 2018
–LA Times Crossword 25 Jun 2018, Monday
-Thomas Joseph – King Feature Syndicate Crossword – Nov 21 2017
Random information on the term “ATOM”:
hAtom is a draft Microformat for marking up (X)HTML, using classes and rel attributes, content on web pages that contain blog entries or similar chronological content. These can then be parsed as feeds in Atom, a web syndication standard.
hAtom is available as version 0.1, released 28 February 2006, and is used widely throughout the Web.
hAtom is also used as the basis for individually subscribable parts of web pages, called Web Slices, which are understood by Internet Explorer 8 and can be understood by Firefox, using third-party add-ons.
The annotations indicated via the hAtom tags added to mark-up determine the portions of content obtained via the Web Slice filter.
Random information on the term “IOTA”:
Latin iota (majuscule: Ɩ, minuscule: ɩ) is a letter of the Latin alphabet, based on the lowercase of the Greek letter iota (ι).
It was formerly used in the International Phonetic Alphabet to represent the vowel in English “bit”. It was replaced by a small capital I (ɪ) in 1989, but it can still be found in use in some later works.
Ɩ has been adopted as a letter in the alphabets of some African languages, such as Kabiyé or Mossi. Its capital form has a hook to distinguish it from capital I. The dotted or accented italic form ɩ is very often indistinguishable from the italic letter small I i in serif fonts.
Random information on the term “ION”:
In Plato’s Ion (/ˈaɪɒn/; Greek: Ἴων) Socrates discusses with the titular character, a professional rhapsode who also lectures on Homer, the question of whether the rhapsode, a performer of poetry, gives his performance on account of his skill and knowledge or by virtue of divine possession. It is one of the shortest of Plato’s dialogues.
Ion has just come from a festival of Asclepius at the city of Epidaurus, after having won first prize in the competition. Socrates engages Ion in a philosophical discussion. Ion admits when Socrates asks, that his skill in performance recitation is limited to Homer, and that all other poets bore him. Socrates finds this puzzling, and sets out to solve the “riddle” of Ion’s limited expertise. He points out to Ion that art critics and judges of sculpture normally do not limit themselves to judging the work of only a single artist, but can criticize the art no matter who the particular artist.
Socrates deduces from this observation that Ion has no real skill, but is like a soothsayer or prophet in being divinely possessed:
Random information on the term “PROTON”:
Proton pump inhibitors (PPIs) are a group of drugs whose main action is a pronounced and long-lasting reduction of gastric acid production. Within the class of medications, there is no clear evidence that one agent works better than another.
They are the most potent inhibitors of acid secretion available. This group of drugs followed and largely superseded another group of medications with similar effects, but a different mode of action, called H2-receptor antagonists.
PPIs are among the most widely sold drugs in the world, and the first one, omeprazole, is on the WHO Model List of Essential Medicines. The cost between different agents varies significantly.
These drugs are used in the treatment of many conditions, such as:
Specialty professional organizations recommend that people take the lowest effective PPI dose to achieve the desired therapeutic result when used to treat gastroesophageal reflux disease long-term. In the United States, the Food and Drug Administration has advised that no more than three 14-day treatment courses should be used in one year.